Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Nature Immunology
|
March 5, 2021
Wnt-β-catenin activation epigenetically reprograms T<sub>reg</sub> cells in inflammatory bowel disease and dysplastic progression
Jasmin Quandt, Stephen Arnovitz, Leila Haghi, et al.
Plos One
|
October 12, 2012
Tumor endothelial inflammation predicts clinical outcome in diverse human cancers
Sean P Pitroda, Tong Zhou, Randy F Sweis, et al.
Nature Medicine
|
January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Timothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Immunity
|
February 10, 2021
Germline genetic contribution to the immune landscape of cancer
Rosalyn W Sayaman, Mohamad Saad, Vésteinn Thorsson, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Cancer Immunology Research
|
April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Maria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
JAMA Oncology
|
November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer
Andrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Cancer Cell
|
December 29, 2023
Melanoma and microbiota: Current understanding and future directions
Bertrand Routy, Tanisha Jackson, Laura Mählmann, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Nature Immunology
|
March 5, 2021
Wnt-β-catenin activation epigenetically reprograms T<sub>reg</sub> cells in inflammatory bowel disease and dysplastic progression
Jasmin Quandt, Stephen Arnovitz, Leila Haghi, et al.
Plos One
|
October 12, 2012
Tumor endothelial inflammation predicts clinical outcome in diverse human cancers
Sean P Pitroda, Tong Zhou, Randy F Sweis, et al.
Nature Medicine
|
January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Timothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Immunity
|
February 10, 2021
Germline genetic contribution to the immune landscape of cancer
Rosalyn W Sayaman, Mohamad Saad, Vésteinn Thorsson, et al.
European Urology Oncology
|
December 17, 2023
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, et al.
Cancer Immunology Research
|
April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Maria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
JAMA Oncology
|
November 1, 2019
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer
Andrea B Apolo, Matthew I Milowsky, Lauren Kim, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Cancer Cell
|
December 29, 2023
Melanoma and microbiota: Current understanding and future directions
Bertrand Routy, Tanisha Jackson, Laura Mählmann, et al.
Page
of 6